ArticleIranian journal of pharmaceutical research : IJPR
Protective Effect of Soy Lecithin Liposomes in Oxazolone-Induced Dermatitis in a Mouse Model: A Comparative Evaluation.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itching, severe erosion, and rashes on the skin surface. Prolonged AD may cause hemorrhage and secondary infections due to scratching. Objectives: This study aimed to investigate the anti-AD effects of soy lecithin (SL) applied topically to oxazolone (OX)-treated skin in a mouse model. Methods: The effects of SL and hydrocortisone (HC), used as the standard drug, on behavioral responses such as scratching and grooming were evaluated during a 35-day trial. Histopathology and immunohistochemistry (IHC) for the cytokines TNFα and IL8 were also evaluated in the skin of the treated mice. Results: Topical administration of SL showed efficacy comparable to that of HC and significantly alleviated itching and grooming behaviors in eczematous animals. Topical SL also improved symptoms, including skin erythema, scarring, and edema, as well as histopathological parameters in AD mice. IHC analysis indicated that SL administration effectively reduced tissue levels of the inflammatory cytokines TNFα and IL8 in AD mice. Conclusions: Topical SL significantly improved AD severity in an OX-induced mouse model of AD. These results support further preclinical studies before clinical investigations in humans are undertaken.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.